首页 > 最新文献

Lung Cancer Management最新文献

英文 中文
How equitable is access to treatment for lung cancer patients? A population-based review of treatment practices in Ontario. 肺癌患者获得治疗的公平程度如何?基于人群的安大略省治疗实践综述。
IF 2.8 Q3 Medicine Pub Date : 2017-12-01 DOI: 10.2217/lmt-2017-0013
William K Evans, Jennifer Stiff, Kelly J Woltman, Yee C Ung, Sue Su-Myat, Phongsack Manivong, Kyle Tsang, Narges Nazen-Rad, Aryn Gatto, Ashley Tyrrell, Rebecca Anas, Gail Darling, Carol Sawka

Aim: Guideline concordance is one of the metrics used by the Cancer Quality Council of Ontario and Cancer Care Ontario to assess the quality of cancer care and to drive quality improvement.

Materials & methods: The rates for lung cancer surgical resection and concordance with the Cancer Care Ontario postoperative adjuvant chemotherapy (AC) guideline were assessed by health region during two time periods (2010-2011 and 2012-2013) according to five equity measures (age, sex, neighborhood income, location of residence and size of immigrant population).

Results: Of the patients with stage I/II NSCLC, 52.2% to 63.0% underwent surgical resection in the province of Ontario, Canada; for patients with stage IIIA disease, the rate was 26.4%. The probability of a surgical resection decreased substantially with age; only 26.9% of those with potentially resectable (stage I-IIIA) disease over 80 years underwent surgery. The use of postoperative AC increased modestly over the time of the study but the rate of use varied widely by health region (34.6 to 84.6%). Patients in rural areas were as likely to receive AC as urban dwellers; however, older aged patients (≥65 years) and those from the lowest income neighborhoods were significantly less likely to receive AC.

Conclusion: Surgical rates and the use of AC vary by health region in Ontario and by age and level of neighborhood income despite universal access in a publicly funded health care system. The reasons for this variance are unclear but warrant further study.Presented in part at the 15th World Conference on Lung Cancer, Sydney, Australia, 27-30 October 2013.

目的:指南一致性是安大略省癌症质量委员会和安大略省癌症护理机构用于评估癌症护理质量并推动质量改进的指标之一。材料与方法:根据5项公平指标(年龄、性别、邻里收入、居住地和移民人口规模),对2010-2011年和2012-2013年两个时期(cancer Care Ontario术后辅助化疗指南)的肺癌手术切除率和一致性进行卫生区域评估。结果:在加拿大安大略省的I/II期NSCLC患者中,52.2%至63.0%的患者接受了手术切除;对于IIIA期患者,这一比例为26.4%。手术切除的可能性随着年龄的增长而显著降低;在80岁以上的可切除(I-IIIA期)患者中,只有26.9%接受了手术。在研究期间,术后AC的使用略有增加,但不同卫生区域的使用率差异很大(34.6%至84.6%)。农村地区的患者接受AC治疗的可能性与城市居民相同;然而,年龄较大的患者(≥65岁)和来自最低收入社区的患者接受AC的可能性明显较低。结论:尽管在公共资助的卫生保健系统中普遍可获得AC,但安大略省的手术率和AC的使用因卫生地区、年龄和社区收入水平而异。这种差异的原因尚不清楚,但值得进一步研究。于2013年10月27日至30日在澳大利亚悉尼举行的第15届世界肺癌大会上部分提交。
{"title":"How equitable is access to treatment for lung cancer patients? A population-based review of treatment practices in Ontario.","authors":"William K Evans,&nbsp;Jennifer Stiff,&nbsp;Kelly J Woltman,&nbsp;Yee C Ung,&nbsp;Sue Su-Myat,&nbsp;Phongsack Manivong,&nbsp;Kyle Tsang,&nbsp;Narges Nazen-Rad,&nbsp;Aryn Gatto,&nbsp;Ashley Tyrrell,&nbsp;Rebecca Anas,&nbsp;Gail Darling,&nbsp;Carol Sawka","doi":"10.2217/lmt-2017-0013","DOIUrl":"https://doi.org/10.2217/lmt-2017-0013","url":null,"abstract":"<p><strong>Aim: </strong>Guideline concordance is one of the metrics used by the Cancer Quality Council of Ontario and Cancer Care Ontario to assess the quality of cancer care and to drive quality improvement.</p><p><strong>Materials & methods: </strong>The rates for lung cancer surgical resection and concordance with the Cancer Care Ontario postoperative adjuvant chemotherapy (AC) guideline were assessed by health region during two time periods (2010-2011 and 2012-2013) according to five equity measures (age, sex, neighborhood income, location of residence and size of immigrant population).</p><p><strong>Results: </strong>Of the patients with stage I/II NSCLC, 52.2% to 63.0% underwent surgical resection in the province of Ontario, Canada; for patients with stage IIIA disease, the rate was 26.4%. The probability of a surgical resection decreased substantially with age; only 26.9% of those with potentially resectable (stage I-IIIA) disease over 80 years underwent surgery. The use of postoperative AC increased modestly over the time of the study but the rate of use varied widely by health region (34.6 to 84.6%). Patients in rural areas were as likely to receive AC as urban dwellers; however, older aged patients (≥65 years) and those from the lowest income neighborhoods were significantly less likely to receive AC.</p><p><strong>Conclusion: </strong>Surgical rates and the use of AC vary by health region in Ontario and by age and level of neighborhood income despite universal access in a publicly funded health care system. The reasons for this variance are unclear but warrant further study.Presented in part at the 15th World Conference on Lung Cancer, Sydney, Australia, 27-30 October 2013.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2017-0013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36853476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer. 关注alk重排非小细胞肺癌的治疗。
IF 2.8 Q3 Medicine Pub Date : 2017-12-01 Epub Date: 2018-06-22 DOI: 10.2217/lmt-2018-0004
Hirva Mamdani, Shadia I Jalal
Lung cancer is the leading cause of cancer-related mortality, both worldwide and in the USA. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. At the turn of 21st century, platinum based cytotoxic chemotherapy was shown to offer modest survival benefit in metastatic NSCLC and remained the only viable treatment option for a long time. Over the past decade, the therapeutic landscape of NSCLC has expanded dramatically owing to the discovery of various driver mutations. Several molecularly targeted agents and immune checkpoint inhibitors are now a part of the therapeutic armamentarium against this genetically complex disease. ALK gene encodes for a member of insulin receptor superfamily transmembrane receptor tyrosine kinase [1]. In 2007, chromosomal rearrangement involving ALK gene on chromosome 2 and EML4 gene on chromosome 5 was first found to have potent transforming activity in NSCLC. Subsequently, preclinical studies suggested that this fusion gene might be the driver mutation and potentially be a therapeutic target of NSCLC [2]. Approximately, 3– 7% of patients with NSCLC harbor the EML4–ALK gene rearrangement, which is mutually exclusive with EGFR and KRAS mutations. ALK gene rearrangements are more common in younger patients with adenocarcinoma histology and those with minimal or no smoking history. There are reports of ALK gene rearrangement in patients with squamous cell and small-cell lung cancer; however, its clinical significance and potential as a therapeutic target in these histologic subtypes remain unknown. The testing modalities for ALK rearrangement in NSCLC include immunohistochemistry (IHC), FISH, and PCR; with the former two being the most commonly utilized modalities. However, there is a variable rate of discordance in response to ALK inhibition in IHC-negative but FISH-positive tumors, and therefore both IHC and FISH are currently recommended for ALK testing. Crizotinib, originally developed as a c-MET inhibitor, is the first-in-class ALK inhibitor to show activity in ALKrearranged NSCLC. In addition, it is also active in ROS1-rearranged lung cancer. Crizotinib received accelerated US FDA approval in 2011 based on a Phase I trial showing objective response rate (ORR) of 60% with a median progression free survival (PFS) of 9.7 months and 12-month overall survival of 74.8% in patients with ALK-rearranged NSCLC [3]. Subsequently, two randomized Phase III trials comparing crizotinib with standard chemotherapy in second line and first-line settings confirmed significantly higher response rates and longer PFS with crizotinib. No statistically significant overall survival difference was observed in either of these trials, largely accounted for by significant crossover between the two arms [4,5]. Despite the striking results with this first ALK inhibitor, the success in personalized therapy was fraught with several challenges. First, the majority of patients develop resistance to crizotinib w
{"title":"Spotlight on the treatment of <i>ALK</i>-rearranged non-small-cell lung cancer.","authors":"Hirva Mamdani,&nbsp;Shadia I Jalal","doi":"10.2217/lmt-2018-0004","DOIUrl":"https://doi.org/10.2217/lmt-2018-0004","url":null,"abstract":"Lung cancer is the leading cause of cancer-related mortality, both worldwide and in the USA. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. At the turn of 21st century, platinum based cytotoxic chemotherapy was shown to offer modest survival benefit in metastatic NSCLC and remained the only viable treatment option for a long time. Over the past decade, the therapeutic landscape of NSCLC has expanded dramatically owing to the discovery of various driver mutations. Several molecularly targeted agents and immune checkpoint inhibitors are now a part of the therapeutic armamentarium against this genetically complex disease. ALK gene encodes for a member of insulin receptor superfamily transmembrane receptor tyrosine kinase [1]. In 2007, chromosomal rearrangement involving ALK gene on chromosome 2 and EML4 gene on chromosome 5 was first found to have potent transforming activity in NSCLC. Subsequently, preclinical studies suggested that this fusion gene might be the driver mutation and potentially be a therapeutic target of NSCLC [2]. Approximately, 3– 7% of patients with NSCLC harbor the EML4–ALK gene rearrangement, which is mutually exclusive with EGFR and KRAS mutations. ALK gene rearrangements are more common in younger patients with adenocarcinoma histology and those with minimal or no smoking history. There are reports of ALK gene rearrangement in patients with squamous cell and small-cell lung cancer; however, its clinical significance and potential as a therapeutic target in these histologic subtypes remain unknown. The testing modalities for ALK rearrangement in NSCLC include immunohistochemistry (IHC), FISH, and PCR; with the former two being the most commonly utilized modalities. However, there is a variable rate of discordance in response to ALK inhibition in IHC-negative but FISH-positive tumors, and therefore both IHC and FISH are currently recommended for ALK testing. Crizotinib, originally developed as a c-MET inhibitor, is the first-in-class ALK inhibitor to show activity in ALKrearranged NSCLC. In addition, it is also active in ROS1-rearranged lung cancer. Crizotinib received accelerated US FDA approval in 2011 based on a Phase I trial showing objective response rate (ORR) of 60% with a median progression free survival (PFS) of 9.7 months and 12-month overall survival of 74.8% in patients with ALK-rearranged NSCLC [3]. Subsequently, two randomized Phase III trials comparing crizotinib with standard chemotherapy in second line and first-line settings confirmed significantly higher response rates and longer PFS with crizotinib. No statistically significant overall survival difference was observed in either of these trials, largely accounted for by significant crossover between the two arms [4,5]. Despite the striking results with this first ALK inhibitor, the success in personalized therapy was fraught with several challenges. First, the majority of patients develop resistance to crizotinib w","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2018-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36853479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
NRG1: a cinderella fusion in lung cancer? NRG1:肺癌的灰姑娘融合?
IF 2.8 Q3 Medicine Pub Date : 2017-12-01 Epub Date: 2018-01-05 DOI: 10.2217/lmt-2017-0018
Lucia Anna Muscarella, Antonio Rossi
Since NRG1 fusions act through the activation of the ERBB receptor, blocking the activity of the NRG1–ERBB–PI3K–AKT pathway might be the best strategy for the treatment of NRG1 -fused tumors.
{"title":"<i>NRG1</i>: a cinderella fusion in lung cancer?","authors":"Lucia Anna Muscarella,&nbsp;Antonio Rossi","doi":"10.2217/lmt-2017-0018","DOIUrl":"https://doi.org/10.2217/lmt-2017-0018","url":null,"abstract":"Since NRG1 fusions act through the activation of the ERBB receptor, blocking the activity of the NRG1–ERBB–PI3K–AKT pathway might be the best strategy for the treatment of NRG1 -fused tumors.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2017-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36853478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Severe intestinal ischemia during chemotherapy for small cell lung cancer. 小细胞肺癌化疗期间严重肠缺血。
IF 2.8 Q3 Medicine Pub Date : 2017-12-01 DOI: 10.2217/lmt-2017-0016
Barbara Legius, Kristiaan Nackaerts

Thromboembolic events (TEEs) are frequent in cancer patients, especially venous thrombosis. Arterial thrombosis is less frequent. Chemotherapy increases the risk of these TEEs. Although TEEs are often reported, intestinal ischemia is a rare complication in cancer patients treated with chemotherapy. Here we describe a rare case of a patient with small cell lung cancer, who developed intestinal ischemia during treatment with cisplatin-etoposide chemotherapy. Shock and multiple organ failure developed and an urgent laparotomy with total colectomy was necessary. This case and review of the literature show that overall arterial TEEs are not as infrequent and may rarely manifest as intestinal ischemia. A cardiovascular assessment before the start of anticancer therapy is therefore imperative for cancer patients.

血栓栓塞事件(tee)在癌症患者中很常见,尤其是静脉血栓形成。动脉血栓形成较少。化疗增加了这些tee的风险。虽然tee经常被报道,但肠缺血是癌症化疗患者中一种罕见的并发症。我们在此报告一例罕见的小细胞肺癌患者,在顺铂-依托泊苷化疗期间发生肠缺血。出现休克和多器官衰竭,需要紧急剖腹手术并全结肠切除术。本病例和文献综述表明,整体动脉tee并不罕见,也很少表现为肠缺血。因此,对癌症患者来说,在开始抗癌治疗之前进行心血管评估是必要的。
{"title":"Severe intestinal ischemia during chemotherapy for small cell lung cancer.","authors":"Barbara Legius,&nbsp;Kristiaan Nackaerts","doi":"10.2217/lmt-2017-0016","DOIUrl":"https://doi.org/10.2217/lmt-2017-0016","url":null,"abstract":"<p><p>Thromboembolic events (TEEs) are frequent in cancer patients, especially venous thrombosis. Arterial thrombosis is less frequent. Chemotherapy increases the risk of these TEEs. Although TEEs are often reported, intestinal ischemia is a rare complication in cancer patients treated with chemotherapy. Here we describe a rare case of a patient with small cell lung cancer, who developed intestinal ischemia during treatment with cisplatin-etoposide chemotherapy. Shock and multiple organ failure developed and an urgent laparotomy with total colectomy was necessary. This case and review of the literature show that overall arterial TEEs are not as infrequent and may rarely manifest as intestinal ischemia. A cardiovascular assessment before the start of anticancer therapy is therefore imperative for cancer patients.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2017-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36854076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Loss of flexion during bronchoscopy: a physical experiment and case study of commercially available systems. 支气管镜检查时屈曲损失:一项物理实验和商用系统的案例研究。
IF 2.8 Q3 Medicine Pub Date : 2017-12-01 DOI: 10.2217/lmt-2017-0012
Conor O'Shea, Kashif Ali Khan, Josef Tugwell, Pádraig Cantillon-Murphy, Marcus P Kennedy

During routine endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) procedures, especially with biopsy of lymph nodes in or around the left upper lobe, frequent reports have noted the loss of ultrasound image and needle angulation leading to an inability to biopsy nodes visualised by EBUS. The aim of this research was to investigate and compare this loss of angulation with commercially available scopes. Bench-top experiments and a clinical case study demonstrated the varying loss of scope angulation, flexibility and manoeuvrability with different scopes and biopsy instruments leading to procedural implications. Improvements in both the EBUS scope and needle characteristics are required to overcome this limitation which has implications in bronchoscope navigation and the diagnostic yield of EBUS-TBNA.

在常规的支气管超声引导下经支气管穿刺(EBUS- tbna)手术中,特别是在左上叶或周围的淋巴结活检中,经常有报道指出超声图像的丢失和针头成角导致无法对EBUS可见的淋巴结进行活检。本研究的目的是调查和比较这种角度损失与市售瞄准镜。台式实验和临床病例研究表明,不同的范围和活检仪器导致不同的范围角度、灵活性和可操作性的损失,从而导致手术上的影响。为了克服这一限制,需要改进EBUS镜和针的特性,这对支气管镜导航和EBUS- tbna的诊断率都有影响。
{"title":"Loss of flexion during bronchoscopy: a physical experiment and case study of commercially available systems.","authors":"Conor O'Shea,&nbsp;Kashif Ali Khan,&nbsp;Josef Tugwell,&nbsp;Pádraig Cantillon-Murphy,&nbsp;Marcus P Kennedy","doi":"10.2217/lmt-2017-0012","DOIUrl":"https://doi.org/10.2217/lmt-2017-0012","url":null,"abstract":"<p><p>During routine endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) procedures, especially with biopsy of lymph nodes in or around the left upper lobe, frequent reports have noted the loss of ultrasound image and needle angulation leading to an inability to biopsy nodes visualised by EBUS. The aim of this research was to investigate and compare this loss of angulation with commercially available scopes. Bench-top experiments and a clinical case study demonstrated the varying loss of scope angulation, flexibility and manoeuvrability with different scopes and biopsy instruments leading to procedural implications. Improvements in both the EBUS scope and needle characteristics are required to overcome this limitation which has implications in bronchoscope navigation and the diagnostic yield of EBUS-TBNA.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2017-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36854078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. 晚期癌症:治疗选择、未来方向、未满足的需求和单中心调查结果。
IF 2.8 Q3 Medicine Pub Date : 2017-12-01 DOI: 10.2217/lmt-2017-0011
Valentina Bertaglia, Stefania Vallone, Maria Vittoria Pacchiana, Silvia Novello

Lung cancer is the leading cause of cancer-related deaths in worldwide, and NSCLC represents around 85% of all lung cancers. Squamous cell lung cancer (SqCLC) is the second most common subtype and it is challenging to treat. New options have been discovered but progresses are still limited for the lack of 'druggable' mutations. Specific resources for SqCLC are limited and this condition affects treatment and outcomes. This paper describes available and emerging therapeutic options and resources that may help patients to face their disease. We have also performed a monocentric survey collecting information about smoking habit and sense of guilty and analyzed the possibility for patients to find helpful sources for their disease. The results suggest that more materials focused on SqCLC are still needed.

癌症是全球癌症相关死亡的主要原因,NSCLC约占所有肺癌的85%。癌症鳞状细胞肺癌(SqCLC)是第二常见的亚型,其治疗具有挑战性。新的选择已经被发现,但由于缺乏“可药用”突变,进展仍然有限。SqCLC的具体资源有限,这种情况会影响治疗和结果。本文介绍了现有的和新兴的治疗选择和资源,这些选择和资源可能有助于患者面对自己的疾病。我们还进行了一项单中心调查,收集了有关吸烟习惯和内疚感的信息,并分析了患者为其疾病寻找有用来源的可能性。研究结果表明,仍然需要更多关注SqCLC的材料。
{"title":"Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey.","authors":"Valentina Bertaglia,&nbsp;Stefania Vallone,&nbsp;Maria Vittoria Pacchiana,&nbsp;Silvia Novello","doi":"10.2217/lmt-2017-0011","DOIUrl":"10.2217/lmt-2017-0011","url":null,"abstract":"<p><p>Lung cancer is the leading cause of cancer-related deaths in worldwide, and NSCLC represents around 85% of all lung cancers. Squamous cell lung cancer (SqCLC) is the second most common subtype and it is challenging to treat. New options have been discovered but progresses are still limited for the lack of 'druggable' mutations. Specific resources for SqCLC are limited and this condition affects treatment and outcomes. This paper describes available and emerging therapeutic options and resources that may help patients to face their disease. We have also performed a monocentric survey collecting information about smoking habit and sense of guilty and analyzed the possibility for patients to find helpful sources for their disease. The results suggest that more materials focused on SqCLC are still needed.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2017-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36854079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Treatment for non-small-cell lung cancer and circulating tumor cells. 治疗非小细胞肺癌和循环肿瘤细胞。
IF 2.8 Q3 Medicine Pub Date : 2017-12-01 Epub Date: 2018-06-22 DOI: 10.2217/lmt-2017-0019
Joel Mason, Benjamin Blyth, Michael P MacManus, Olga A Martin

Surgery is the main curative therapy for patients with localized non-small-cell lung cancer while radiotherapy (RT), alone or with concurrent platinum-based chemotherapy, remains the primary curative modality for locoregionally advanced non-small-cell lung cancer. The risk of distant metastasis is high after curative-intent treatment, largely attributable to the presence of undetected micrometastases, but which could also be related to treatment-related increases in circulating tumor cells (CTCs). CTC mobilization by RT or systemic therapies might either reflect efficient tumor destruction with improved prognosis, or might promote metastasis and thus represent a potential therapeutic target. RT may induce prometastatic biological alterations in CTC at the cellular level, which are detectable by 'liquid biopsies', though their rarity represents a major challenge. Improved methods of isolation and ex vivo propagation will be essential for the future of CTC research.

手术是局部非小细胞肺癌患者的主要根治疗法,而单独或同时使用铂类化疗的放射治疗(RT)仍是局部晚期非小细胞肺癌的主要根治方式。治愈性治疗后发生远处转移的风险很高,这主要归因于未被发现的微转移灶的存在,但也可能与治疗相关的循环肿瘤细胞(CTC)的增加有关。通过 RT 或全身疗法动员的 CTC 可能反映出肿瘤被有效摧毁,从而改善预后,也可能促进肿瘤转移,从而成为潜在的治疗靶点。RT 可能会在细胞水平上诱导 CTC 发生转移性生物学改变,这种改变可通过 "液体活检 "检测到,但其罕见性是一大挑战。改进分离和体内外繁殖方法对未来的 CTC 研究至关重要。
{"title":"Treatment for non-small-cell lung cancer and circulating tumor cells.","authors":"Joel Mason, Benjamin Blyth, Michael P MacManus, Olga A Martin","doi":"10.2217/lmt-2017-0019","DOIUrl":"10.2217/lmt-2017-0019","url":null,"abstract":"<p><p>Surgery is the main curative therapy for patients with localized non-small-cell lung cancer while radiotherapy (RT), alone or with concurrent platinum-based chemotherapy, remains the primary curative modality for locoregionally advanced non-small-cell lung cancer. The risk of distant metastasis is high after curative-intent treatment, largely attributable to the presence of undetected micrometastases, but which could also be related to treatment-related increases in circulating tumor cells (CTCs). CTC mobilization by RT or systemic therapies might either reflect efficient tumor destruction with improved prognosis, or might promote metastasis and thus represent a potential therapeutic target. RT may induce prometastatic biological alterations in CTC at the cellular level, which are detectable by 'liquid biopsies', though their rarity represents a major challenge. Improved methods of isolation and <i>ex vivo</i> propagation will be essential for the future of CTC research.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36853480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient with typical carcinoid initially diagnosed as high-grade neuroendocrine carcinoma. 患者患有典型类癌,最初被诊断为高级别神经内分泌癌。
IF 2.8 Q3 Medicine Pub Date : 2017-11-01 Epub Date: 2017-10-26 DOI: 10.2217/lmt-2017-0010
Sean Warsch, Mohammad Jahanzeb

We report the case of a patient initially diagnosed with a high-grade neuroendocrine carcinoma, which 5 years later was determined to have a low-grade typical carcinoid. The patient received radiotherapy and numerous chemotherapy regimens for treatment of a high-grade metastatic mixed large and small cell neuroendocrine carcinoma, without a significant response to any treatment. Subsequent imaging revealed widely metastatic disease and computed tomography-guided biopsy demonstrated a carcinoid tumor with no necrosis. The patient was started on temozolomide + capecitabine, long-acting octreotide and denosumab, with everolimus planned upon disease progression. Findings from this case study highlight the importance of accurate histopathologic classification of thoracic neuroendocrine tumors at diagnosis, to avoid the unnecessary administration of aggressive chemotherapy to patients with low-grade tumors.

我们报告了一例最初被诊断为高级别神经内分泌癌的患者,5 年后被确定为低级别典型类癌。患者接受了放射治疗和多种化疗方案,以治疗高级别转移性大、小细胞混合型神经内分泌癌,但对任何治疗均无明显反应。随后的影像学检查发现了广泛的转移性疾病,计算机断层扫描引导下的活组织检查显示患者患有类癌,但没有坏死。患者开始接受替莫唑胺+卡培他滨、长效奥曲肽和地诺单抗治疗,并计划在疾病进展后接受依维莫司治疗。本病例的研究结果凸显了在诊断时对胸部神经内分泌肿瘤进行准确组织病理学分类的重要性,以避免对低分级肿瘤患者进行不必要的侵袭性化疗。
{"title":"Patient with typical carcinoid initially diagnosed as high-grade neuroendocrine carcinoma.","authors":"Sean Warsch, Mohammad Jahanzeb","doi":"10.2217/lmt-2017-0010","DOIUrl":"10.2217/lmt-2017-0010","url":null,"abstract":"<p><p>We report the case of a patient initially diagnosed with a high-grade neuroendocrine carcinoma, which 5 years later was determined to have a low-grade typical carcinoid. The patient received radiotherapy and numerous chemotherapy regimens for treatment of a high-grade metastatic mixed large and small cell neuroendocrine carcinoma, without a significant response to any treatment. Subsequent imaging revealed widely metastatic disease and computed tomography-guided biopsy demonstrated a carcinoid tumor with no necrosis. The patient was started on temozolomide + capecitabine, long-acting octreotide and denosumab, with everolimus planned upon disease progression. Findings from this case study highlight the importance of accurate histopathologic classification of thoracic neuroendocrine tumors at diagnosis, to avoid the unnecessary administration of aggressive chemotherapy to patients with low-grade tumors.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/38/ba/lmt-06-41.PMC6310322.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36854074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The prognostic value of serum and bronchoalveolar lavage levels of adiponectin in advanced non-small-cell lung cancer. 晚期非小细胞肺癌患者血清和支气管肺泡灌洗液中脂联素水平的预后价值。
IF 2.8 Q3 Medicine Pub Date : 2017-11-01 Epub Date: 2017-11-17 DOI: 10.2217/lmt-2016-0018
Paraskevi Boura, Dimitra Grapsa, Stylianos Loukides, Maria Angelidou, Konstantina Tsakanika, Nikolaos Syrigos, Ioannis Gkiozos

Aim: We aimed to explore the prognostic implications of adiponectin (APN) levels in the serum and bronchoalveolar lavage (BAL) of patients with advanced NSCLC.

Materials & methods: 29 newly diagnosed patients with stage IV NSCLC were prospectively enrolled. Baseline serum and BAL levels of APN were assayed by ELISA and correlated with various clinicopathological parameters, including overall survival.

Results: No statistically significant correlations were observed between the serum or BAL levels of APN and the clinicopathological parameters evaluated. The only prognostic factor identified, both by univariate and multivariate survival analyses, was performance status.

Conclusion: The results of our cohort failed to reveal any prognostic significance of serum and BAL levels of APN in stage IV NSCLC.

目的:我们旨在探讨晚期NSCLC患者血清和支气管肺泡灌洗(BAL)中脂联素(APN)水平对预后的影响。材料与方法:前瞻性纳入29例新诊断的IV期NSCLC患者。采用ELISA检测APN的基线血清和BAL水平,并与各种临床病理参数(包括总生存率)相关。结果:血清或BAL水平与APN的临床病理参数无统计学意义的相关性。通过单变量和多变量生存分析,唯一确定的预后因素是表现状态。结论:我们的队列结果未能揭示血清和BAL水平的APN在IV期NSCLC中的预后意义。
{"title":"The prognostic value of serum and bronchoalveolar lavage levels of adiponectin in advanced non-small-cell lung cancer.","authors":"Paraskevi Boura,&nbsp;Dimitra Grapsa,&nbsp;Stylianos Loukides,&nbsp;Maria Angelidou,&nbsp;Konstantina Tsakanika,&nbsp;Nikolaos Syrigos,&nbsp;Ioannis Gkiozos","doi":"10.2217/lmt-2016-0018","DOIUrl":"https://doi.org/10.2217/lmt-2016-0018","url":null,"abstract":"<p><strong>Aim: </strong>We aimed to explore the prognostic implications of adiponectin (APN) levels in the serum and bronchoalveolar lavage (BAL) of patients with advanced NSCLC.</p><p><strong>Materials & methods: </strong>29 newly diagnosed patients with stage IV NSCLC were prospectively enrolled. Baseline serum and BAL levels of APN were assayed by ELISA and correlated with various clinicopathological parameters, including overall survival.</p><p><strong>Results: </strong>No statistically significant correlations were observed between the serum or BAL levels of APN and the clinicopathological parameters evaluated. The only prognostic factor identified, both by univariate and multivariate survival analyses, was performance status.</p><p><strong>Conclusion: </strong>The results of our cohort failed to reveal any prognostic significance of serum and BAL levels of APN in stage IV NSCLC.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2016-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36853477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The route to diagnosis: emergency presentation of lung cancer. 诊断途径:肺癌的紧急表现。
IF 2.8 Q3 Medicine Pub Date : 2017-11-01 Epub Date: 2017-11-17 DOI: 10.2217/lmt-2017-0004
Thomas Newsom-Davis

A significant proportion of lung cancer patients are first diagnosed as part of an emergency presentation (EP) to acute medical services. This route to diagnosis is a strong negative predictor of survival, and is associated with age, deprivation and medical co-morbidities. Patients are less likely to receive anticancer treatment than those diagnosed through elective routes. The causes of EP of cancer are complex. When it is unavoidable, prompt input from specialist lung cancer services is needed. Preventing EP of lung cancer involves streamlined diagnostic pathways, public health campaigns about symptoms, decision-support tools for general practitioners, improved communication and access for primary and secondary care, and focus on vague symptoms. Reducing EP of lung cancer is important when improving outcomes and patient experience.

相当大比例的肺癌患者是作为急诊医疗服务的一部分首次诊断出来的。这种诊断途径是生存的强烈负面预测因素,并与年龄、贫困和医疗合并症有关。患者接受抗癌治疗的可能性低于通过选择性途径确诊的患者。癌症诱发EP的原因很复杂。当不可避免时,需要专家肺癌服务部门及时提供意见。预防肺癌EP包括简化诊断途径,开展关于症状的公共卫生运动,为全科医生提供决策支持工具,改善初级和二级保健的沟通和获取,并关注模糊症状。降低肺癌的EP对于改善预后和患者体验非常重要。
{"title":"The route to diagnosis: emergency presentation of lung cancer.","authors":"Thomas Newsom-Davis","doi":"10.2217/lmt-2017-0004","DOIUrl":"https://doi.org/10.2217/lmt-2017-0004","url":null,"abstract":"<p><p>A significant proportion of lung cancer patients are first diagnosed as part of an emergency presentation (EP) to acute medical services. This route to diagnosis is a strong negative predictor of survival, and is associated with age, deprivation and medical co-morbidities. Patients are less likely to receive anticancer treatment than those diagnosed through elective routes. The causes of EP of cancer are complex. When it is unavoidable, prompt input from specialist lung cancer services is needed. Preventing EP of lung cancer involves streamlined diagnostic pathways, public health campaigns about symptoms, decision-support tools for general practitioners, improved communication and access for primary and secondary care, and focus on vague symptoms. Reducing EP of lung cancer is important when improving outcomes and patient experience.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2017-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36854075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Lung Cancer Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1